nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—CYP3A4—type 2 diabetes mellitus	0.282	1	CbGaD
Everolimus—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0452	0.152	CbGbCtD
Everolimus—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0403	0.136	CbGbCtD
Everolimus—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0368	0.124	CbGbCtD
Everolimus—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0322	0.109	CbGbCtD
Everolimus—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0291	0.0982	CbGbCtD
Everolimus—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0221	0.0744	CbGbCtD
Everolimus—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0211	0.0713	CbGbCtD
Everolimus—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0211	0.0713	CbGbCtD
Everolimus—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.02	0.0675	CbGbCtD
Everolimus—CYP3A4—Glyburide—type 2 diabetes mellitus	0.0149	0.0503	CbGbCtD
Everolimus—CYP3A4—Losartan—type 2 diabetes mellitus	0.0136	0.046	CbGbCtD
Everolimus—MTOR—leg—type 2 diabetes mellitus	0.0102	0.239	CbGeAlD
Everolimus—MTOR—hindlimb—type 2 diabetes mellitus	0.00914	0.214	CbGeAlD
Everolimus—MTOR—retina—type 2 diabetes mellitus	0.0023	0.0538	CbGeAlD
Everolimus—FKBP1A—retina—type 2 diabetes mellitus	0.00207	0.0484	CbGeAlD
Everolimus—MTOR—cardiovascular system—type 2 diabetes mellitus	0.00195	0.0455	CbGeAlD
Everolimus—MTOR—kidney—type 2 diabetes mellitus	0.00191	0.0445	CbGeAlD
Everolimus—MTOR—pancreas—type 2 diabetes mellitus	0.00189	0.0442	CbGeAlD
Everolimus—FKBP1A—cardiovascular system—type 2 diabetes mellitus	0.00175	0.0409	CbGeAlD
Everolimus—MTOR—adipose tissue—type 2 diabetes mellitus	0.00172	0.0401	CbGeAlD
Everolimus—FKBP1A—kidney—type 2 diabetes mellitus	0.00171	0.04	CbGeAlD
Everolimus—FKBP1A—pancreas—type 2 diabetes mellitus	0.0017	0.0398	CbGeAlD
Everolimus—FKBP1A—cortex of kidney—type 2 diabetes mellitus	0.00167	0.039	CbGeAlD
Everolimus—FKBP1A—adipose tissue—type 2 diabetes mellitus	0.00154	0.0361	CbGeAlD
Everolimus—MTOR—liver—type 2 diabetes mellitus	0.0012	0.0281	CbGeAlD
Everolimus—FKBP1A—liver—type 2 diabetes mellitus	0.00108	0.0253	CbGeAlD
Everolimus—Pimecrolimus—CYP3A4—type 2 diabetes mellitus	0.000719	0.296	CrCbGaD
Everolimus—CYP3A4—kidney—type 2 diabetes mellitus	0.00056	0.0131	CbGeAlD
Everolimus—Temsirolimus—CYP3A4—type 2 diabetes mellitus	0.000486	0.2	CrCbGaD
Everolimus—Tacrolimus—CYP3A4—type 2 diabetes mellitus	0.000428	0.176	CrCbGaD
Everolimus—Sirolimus—CYP3A4—type 2 diabetes mellitus	0.000428	0.176	CrCbGaD
Everolimus—Tacrolimus—ALB—type 2 diabetes mellitus	0.000373	0.153	CrCbGaD
Everolimus—CYP3A4—liver—type 2 diabetes mellitus	0.000354	0.00827	CbGeAlD
Everolimus—Flushing—Ramipril—type 2 diabetes mellitus	7.5e-05	0.000309	CcSEcCtD
Everolimus—Angioedema—Losartan—type 2 diabetes mellitus	7.5e-05	0.000309	CcSEcCtD
Everolimus—Infection—Metformin—type 2 diabetes mellitus	7.49e-05	0.000309	CcSEcCtD
Everolimus—Insomnia—Valsartan—type 2 diabetes mellitus	7.49e-05	0.000309	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	7.45e-05	0.000308	CcSEcCtD
Everolimus—Paraesthesia—Valsartan—type 2 diabetes mellitus	7.44e-05	0.000307	CcSEcCtD
Everolimus—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	7.43e-05	0.000306	CcSEcCtD
Everolimus—Arthralgia—Irbesartan—type 2 diabetes mellitus	7.42e-05	0.000306	CcSEcCtD
Everolimus—Myalgia—Irbesartan—type 2 diabetes mellitus	7.42e-05	0.000306	CcSEcCtD
Everolimus—Chest pain—Irbesartan—type 2 diabetes mellitus	7.42e-05	0.000306	CcSEcCtD
Everolimus—Shock—Metformin—type 2 diabetes mellitus	7.42e-05	0.000306	CcSEcCtD
Everolimus—Insomnia—Orlistat—type 2 diabetes mellitus	7.4e-05	0.000305	CcSEcCtD
Everolimus—Malaise—Losartan—type 2 diabetes mellitus	7.4e-05	0.000305	CcSEcCtD
Everolimus—Anxiety—Irbesartan—type 2 diabetes mellitus	7.4e-05	0.000305	CcSEcCtD
Everolimus—Hypersensitivity—Glyburide—type 2 diabetes mellitus	7.39e-05	0.000305	CcSEcCtD
Everolimus—Nervous system disorder—Metformin—type 2 diabetes mellitus	7.39e-05	0.000305	CcSEcCtD
Everolimus—Thrombocytopenia—Metformin—type 2 diabetes mellitus	7.38e-05	0.000305	CcSEcCtD
Everolimus—Dyspnoea—Valsartan—type 2 diabetes mellitus	7.38e-05	0.000305	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	7.37e-05	0.000304	CcSEcCtD
Everolimus—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	7.37e-05	0.000304	CcSEcCtD
Everolimus—Somnolence—Valsartan—type 2 diabetes mellitus	7.36e-05	0.000304	CcSEcCtD
Everolimus—Syncope—Losartan—type 2 diabetes mellitus	7.36e-05	0.000304	CcSEcCtD
Everolimus—Paraesthesia—Orlistat—type 2 diabetes mellitus	7.35e-05	0.000303	CcSEcCtD
Everolimus—Leukopenia—Losartan—type 2 diabetes mellitus	7.34e-05	0.000303	CcSEcCtD
Everolimus—Discomfort—Irbesartan—type 2 diabetes mellitus	7.33e-05	0.000303	CcSEcCtD
Everolimus—Skin disorder—Metformin—type 2 diabetes mellitus	7.32e-05	0.000302	CcSEcCtD
Everolimus—Immune system disorder—Ramipril—type 2 diabetes mellitus	7.3e-05	0.000301	CcSEcCtD
Everolimus—Hyperhidrosis—Metformin—type 2 diabetes mellitus	7.29e-05	0.000301	CcSEcCtD
Everolimus—Dyspepsia—Valsartan—type 2 diabetes mellitus	7.29e-05	0.000301	CcSEcCtD
Everolimus—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	7.28e-05	0.000301	CcSEcCtD
Everolimus—Dizziness—Bromocriptine—type 2 diabetes mellitus	7.26e-05	0.0003	CcSEcCtD
Everolimus—Dry mouth—Irbesartan—type 2 diabetes mellitus	7.26e-05	0.0003	CcSEcCtD
Everolimus—Palpitations—Losartan—type 2 diabetes mellitus	7.25e-05	0.000299	CcSEcCtD
Everolimus—Nausea—Glimepiride—type 2 diabetes mellitus	7.23e-05	0.000298	CcSEcCtD
Everolimus—Loss of consciousness—Losartan—type 2 diabetes mellitus	7.21e-05	0.000298	CcSEcCtD
Everolimus—Nausea—Sitagliptin—type 2 diabetes mellitus	7.21e-05	0.000297	CcSEcCtD
Everolimus—Dyspepsia—Orlistat—type 2 diabetes mellitus	7.2e-05	0.000297	CcSEcCtD
Everolimus—Asthenia—Glyburide—type 2 diabetes mellitus	7.2e-05	0.000297	CcSEcCtD
Everolimus—Decreased appetite—Valsartan—type 2 diabetes mellitus	7.2e-05	0.000297	CcSEcCtD
Everolimus—Anorexia—Metformin—type 2 diabetes mellitus	7.19e-05	0.000297	CcSEcCtD
Everolimus—Cough—Losartan—type 2 diabetes mellitus	7.16e-05	0.000295	CcSEcCtD
Everolimus—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	7.15e-05	0.000295	CcSEcCtD
Everolimus—Alopecia—Ramipril—type 2 diabetes mellitus	7.14e-05	0.000295	CcSEcCtD
Everolimus—Fatigue—Valsartan—type 2 diabetes mellitus	7.14e-05	0.000295	CcSEcCtD
Everolimus—Abdominal pain—Gliclazide—type 2 diabetes mellitus	7.12e-05	0.000294	CcSEcCtD
Everolimus—Body temperature increased—Gliclazide—type 2 diabetes mellitus	7.12e-05	0.000294	CcSEcCtD
Everolimus—Oedema—Irbesartan—type 2 diabetes mellitus	7.12e-05	0.000294	CcSEcCtD
Everolimus—Decreased appetite—Orlistat—type 2 diabetes mellitus	7.11e-05	0.000293	CcSEcCtD
Everolimus—Pruritus—Glyburide—type 2 diabetes mellitus	7.1e-05	0.000293	CcSEcCtD
Everolimus—Mental disorder—Ramipril—type 2 diabetes mellitus	7.08e-05	0.000292	CcSEcCtD
Everolimus—Constipation—Valsartan—type 2 diabetes mellitus	7.08e-05	0.000292	CcSEcCtD
Everolimus—Infection—Irbesartan—type 2 diabetes mellitus	7.07e-05	0.000292	CcSEcCtD
Everolimus—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	7.06e-05	0.000291	CcSEcCtD
Everolimus—Fatigue—Orlistat—type 2 diabetes mellitus	7.05e-05	0.000291	CcSEcCtD
Everolimus—Hypotension—Metformin—type 2 diabetes mellitus	7.05e-05	0.000291	CcSEcCtD
Everolimus—Malnutrition—Ramipril—type 2 diabetes mellitus	7.04e-05	0.00029	CcSEcCtD
Everolimus—Erythema—Ramipril—type 2 diabetes mellitus	7.04e-05	0.00029	CcSEcCtD
Everolimus—Shock—Irbesartan—type 2 diabetes mellitus	7e-05	0.000289	CcSEcCtD
Everolimus—Pain—Orlistat—type 2 diabetes mellitus	7e-05	0.000289	CcSEcCtD
Everolimus—Myalgia—Losartan—type 2 diabetes mellitus	6.99e-05	0.000288	CcSEcCtD
Everolimus—Arthralgia—Losartan—type 2 diabetes mellitus	6.99e-05	0.000288	CcSEcCtD
Everolimus—Chest pain—Losartan—type 2 diabetes mellitus	6.99e-05	0.000288	CcSEcCtD
Everolimus—Vomiting—Bromocriptine—type 2 diabetes mellitus	6.98e-05	0.000288	CcSEcCtD
Everolimus—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	6.98e-05	0.000288	CcSEcCtD
Everolimus—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	6.97e-05	0.000287	CcSEcCtD
Everolimus—Anxiety—Losartan—type 2 diabetes mellitus	6.96e-05	0.000287	CcSEcCtD
Everolimus—Tachycardia—Irbesartan—type 2 diabetes mellitus	6.95e-05	0.000287	CcSEcCtD
Everolimus—Rash—Bromocriptine—type 2 diabetes mellitus	6.92e-05	0.000286	CcSEcCtD
Everolimus—Dermatitis—Bromocriptine—type 2 diabetes mellitus	6.92e-05	0.000285	CcSEcCtD
Everolimus—Skin disorder—Irbesartan—type 2 diabetes mellitus	6.91e-05	0.000285	CcSEcCtD
Everolimus—Discomfort—Losartan—type 2 diabetes mellitus	6.9e-05	0.000285	CcSEcCtD
Everolimus—Dysgeusia—Ramipril—type 2 diabetes mellitus	6.89e-05	0.000284	CcSEcCtD
Everolimus—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	6.88e-05	0.000284	CcSEcCtD
Everolimus—Headache—Bromocriptine—type 2 diabetes mellitus	6.88e-05	0.000284	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	6.87e-05	0.000283	CcSEcCtD
Everolimus—Diarrhoea—Glyburide—type 2 diabetes mellitus	6.87e-05	0.000283	CcSEcCtD
Everolimus—Dry mouth—Losartan—type 2 diabetes mellitus	6.83e-05	0.000282	CcSEcCtD
Everolimus—Anorexia—Irbesartan—type 2 diabetes mellitus	6.78e-05	0.00028	CcSEcCtD
Everolimus—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	6.77e-05	0.000279	CcSEcCtD
Everolimus—Paraesthesia—Metformin—type 2 diabetes mellitus	6.77e-05	0.000279	CcSEcCtD
Everolimus—Muscle spasms—Ramipril—type 2 diabetes mellitus	6.76e-05	0.000279	CcSEcCtD
Everolimus—Feeling abnormal—Orlistat—type 2 diabetes mellitus	6.74e-05	0.000278	CcSEcCtD
Everolimus—Dyspnoea—Metformin—type 2 diabetes mellitus	6.72e-05	0.000277	CcSEcCtD
Everolimus—Somnolence—Metformin—type 2 diabetes mellitus	6.7e-05	0.000277	CcSEcCtD
Everolimus—Oedema—Losartan—type 2 diabetes mellitus	6.7e-05	0.000276	CcSEcCtD
Everolimus—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	6.69e-05	0.000276	CcSEcCtD
Everolimus—Infection—Losartan—type 2 diabetes mellitus	6.65e-05	0.000275	CcSEcCtD
Everolimus—Hypotension—Irbesartan—type 2 diabetes mellitus	6.65e-05	0.000274	CcSEcCtD
Everolimus—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	6.64e-05	0.000274	CcSEcCtD
Everolimus—Dyspepsia—Metformin—type 2 diabetes mellitus	6.64e-05	0.000274	CcSEcCtD
Everolimus—Tremor—Ramipril—type 2 diabetes mellitus	6.59e-05	0.000272	CcSEcCtD
Everolimus—Shock—Losartan—type 2 diabetes mellitus	6.59e-05	0.000272	CcSEcCtD
Everolimus—Nervous system disorder—Losartan—type 2 diabetes mellitus	6.57e-05	0.000271	CcSEcCtD
Everolimus—Thrombocytopenia—Losartan—type 2 diabetes mellitus	6.56e-05	0.000271	CcSEcCtD
Everolimus—Decreased appetite—Metformin—type 2 diabetes mellitus	6.55e-05	0.00027	CcSEcCtD
Everolimus—Abdominal pain—Valsartan—type 2 diabetes mellitus	6.55e-05	0.00027	CcSEcCtD
Everolimus—Tachycardia—Losartan—type 2 diabetes mellitus	6.54e-05	0.00027	CcSEcCtD
Everolimus—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	6.53e-05	0.000269	CcSEcCtD
Everolimus—Nausea—Bromocriptine—type 2 diabetes mellitus	6.52e-05	0.000269	CcSEcCtD
Everolimus—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	6.51e-05	0.000269	CcSEcCtD
Everolimus—Fatigue—Metformin—type 2 diabetes mellitus	6.5e-05	0.000268	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	6.48e-05	0.000267	CcSEcCtD
Everolimus—Hyperhidrosis—Losartan—type 2 diabetes mellitus	6.47e-05	0.000267	CcSEcCtD
Everolimus—Abdominal pain—Orlistat—type 2 diabetes mellitus	6.47e-05	0.000267	CcSEcCtD
Everolimus—Body temperature increased—Orlistat—type 2 diabetes mellitus	6.47e-05	0.000267	CcSEcCtD
Everolimus—Asthenia—Gliclazide—type 2 diabetes mellitus	6.47e-05	0.000267	CcSEcCtD
Everolimus—Agitation—Ramipril—type 2 diabetes mellitus	6.47e-05	0.000267	CcSEcCtD
Everolimus—Constipation—Metformin—type 2 diabetes mellitus	6.45e-05	0.000266	CcSEcCtD
Everolimus—Angioedema—Ramipril—type 2 diabetes mellitus	6.43e-05	0.000265	CcSEcCtD
Everolimus—Paraesthesia—Irbesartan—type 2 diabetes mellitus	6.39e-05	0.000264	CcSEcCtD
Everolimus—Anorexia—Losartan—type 2 diabetes mellitus	6.38e-05	0.000263	CcSEcCtD
Everolimus—Vomiting—Glyburide—type 2 diabetes mellitus	6.38e-05	0.000263	CcSEcCtD
Everolimus—Pruritus—Gliclazide—type 2 diabetes mellitus	6.38e-05	0.000263	CcSEcCtD
Everolimus—Malaise—Ramipril—type 2 diabetes mellitus	6.34e-05	0.000262	CcSEcCtD
Everolimus—Dyspnoea—Irbesartan—type 2 diabetes mellitus	6.34e-05	0.000262	CcSEcCtD
Everolimus—Rash—Glyburide—type 2 diabetes mellitus	6.33e-05	0.000261	CcSEcCtD
Everolimus—Somnolence—Irbesartan—type 2 diabetes mellitus	6.33e-05	0.000261	CcSEcCtD
Everolimus—Dermatitis—Glyburide—type 2 diabetes mellitus	6.32e-05	0.000261	CcSEcCtD
Everolimus—Syncope—Ramipril—type 2 diabetes mellitus	6.31e-05	0.00026	CcSEcCtD
Everolimus—Leukopenia—Ramipril—type 2 diabetes mellitus	6.3e-05	0.00026	CcSEcCtD
Everolimus—Headache—Glyburide—type 2 diabetes mellitus	6.29e-05	0.000259	CcSEcCtD
Everolimus—Dyspepsia—Irbesartan—type 2 diabetes mellitus	6.26e-05	0.000258	CcSEcCtD
Everolimus—Hypotension—Losartan—type 2 diabetes mellitus	6.26e-05	0.000258	CcSEcCtD
Everolimus—Palpitations—Ramipril—type 2 diabetes mellitus	6.22e-05	0.000257	CcSEcCtD
Everolimus—Feeling abnormal—Metformin—type 2 diabetes mellitus	6.21e-05	0.000256	CcSEcCtD
Everolimus—Decreased appetite—Irbesartan—type 2 diabetes mellitus	6.19e-05	0.000255	CcSEcCtD
Everolimus—Loss of consciousness—Ramipril—type 2 diabetes mellitus	6.18e-05	0.000255	CcSEcCtD
Everolimus—Diarrhoea—Gliclazide—type 2 diabetes mellitus	6.17e-05	0.000254	CcSEcCtD
Everolimus—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	6.17e-05	0.000254	CcSEcCtD
Everolimus—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	6.14e-05	0.000253	CcSEcCtD
Everolimus—Cough—Ramipril—type 2 diabetes mellitus	6.14e-05	0.000253	CcSEcCtD
Everolimus—Fatigue—Irbesartan—type 2 diabetes mellitus	6.14e-05	0.000253	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	6.1e-05	0.000252	CcSEcCtD
Everolimus—Hypersensitivity—Valsartan—type 2 diabetes mellitus	6.1e-05	0.000252	CcSEcCtD
Everolimus—Convulsion—Ramipril—type 2 diabetes mellitus	6.1e-05	0.000252	CcSEcCtD
Everolimus—Constipation—Irbesartan—type 2 diabetes mellitus	6.09e-05	0.000251	CcSEcCtD
Everolimus—Pain—Irbesartan—type 2 diabetes mellitus	6.09e-05	0.000251	CcSEcCtD
Everolimus—Insomnia—Losartan—type 2 diabetes mellitus	6.06e-05	0.00025	CcSEcCtD
Everolimus—Hypersensitivity—Orlistat—type 2 diabetes mellitus	6.03e-05	0.000249	CcSEcCtD
Everolimus—Paraesthesia—Losartan—type 2 diabetes mellitus	6.01e-05	0.000248	CcSEcCtD
Everolimus—Arthralgia—Ramipril—type 2 diabetes mellitus	5.99e-05	0.000247	CcSEcCtD
Everolimus—Chest pain—Ramipril—type 2 diabetes mellitus	5.99e-05	0.000247	CcSEcCtD
Everolimus—Myalgia—Ramipril—type 2 diabetes mellitus	5.99e-05	0.000247	CcSEcCtD
Everolimus—Dyspnoea—Losartan—type 2 diabetes mellitus	5.97e-05	0.000246	CcSEcCtD
Everolimus—Anxiety—Ramipril—type 2 diabetes mellitus	5.97e-05	0.000246	CcSEcCtD
Everolimus—Nausea—Glyburide—type 2 diabetes mellitus	5.96e-05	0.000246	CcSEcCtD
Everolimus—Abdominal pain—Metformin—type 2 diabetes mellitus	5.96e-05	0.000246	CcSEcCtD
Everolimus—Dizziness—Gliclazide—type 2 diabetes mellitus	5.96e-05	0.000246	CcSEcCtD
Everolimus—Somnolence—Losartan—type 2 diabetes mellitus	5.95e-05	0.000246	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	5.95e-05	0.000245	CcSEcCtD
Everolimus—Asthenia—Valsartan—type 2 diabetes mellitus	5.94e-05	0.000245	CcSEcCtD
Everolimus—Discomfort—Ramipril—type 2 diabetes mellitus	5.92e-05	0.000244	CcSEcCtD
Everolimus—Dyspepsia—Losartan—type 2 diabetes mellitus	5.89e-05	0.000243	CcSEcCtD
Everolimus—Asthenia—Orlistat—type 2 diabetes mellitus	5.87e-05	0.000242	CcSEcCtD
Everolimus—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	5.86e-05	0.000242	CcSEcCtD
Everolimus—Pruritus—Valsartan—type 2 diabetes mellitus	5.86e-05	0.000242	CcSEcCtD
Everolimus—Dry mouth—Ramipril—type 2 diabetes mellitus	5.86e-05	0.000242	CcSEcCtD
Everolimus—Decreased appetite—Losartan—type 2 diabetes mellitus	5.82e-05	0.00024	CcSEcCtD
Everolimus—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	5.82e-05	0.00024	CcSEcCtD
Everolimus—Pruritus—Orlistat—type 2 diabetes mellitus	5.79e-05	0.000239	CcSEcCtD
Everolimus—Fatigue—Losartan—type 2 diabetes mellitus	5.77e-05	0.000238	CcSEcCtD
Everolimus—Oedema—Ramipril—type 2 diabetes mellitus	5.74e-05	0.000237	CcSEcCtD
Everolimus—Vomiting—Gliclazide—type 2 diabetes mellitus	5.73e-05	0.000236	CcSEcCtD
Everolimus—Pain—Losartan—type 2 diabetes mellitus	5.73e-05	0.000236	CcSEcCtD
Everolimus—Constipation—Losartan—type 2 diabetes mellitus	5.73e-05	0.000236	CcSEcCtD
Everolimus—Rash—Gliclazide—type 2 diabetes mellitus	5.68e-05	0.000234	CcSEcCtD
Everolimus—Dermatitis—Gliclazide—type 2 diabetes mellitus	5.68e-05	0.000234	CcSEcCtD
Everolimus—Diarrhoea—Valsartan—type 2 diabetes mellitus	5.67e-05	0.000234	CcSEcCtD
Everolimus—Shock—Ramipril—type 2 diabetes mellitus	5.65e-05	0.000233	CcSEcCtD
Everolimus—Headache—Gliclazide—type 2 diabetes mellitus	5.65e-05	0.000233	CcSEcCtD
Everolimus—Nervous system disorder—Ramipril—type 2 diabetes mellitus	5.63e-05	0.000232	CcSEcCtD
Everolimus—Body temperature increased—Irbesartan—type 2 diabetes mellitus	5.63e-05	0.000232	CcSEcCtD
Everolimus—Abdominal pain—Irbesartan—type 2 diabetes mellitus	5.63e-05	0.000232	CcSEcCtD
Everolimus—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	5.62e-05	0.000232	CcSEcCtD
Everolimus—Tachycardia—Ramipril—type 2 diabetes mellitus	5.6e-05	0.000231	CcSEcCtD
Everolimus—Diarrhoea—Orlistat—type 2 diabetes mellitus	5.6e-05	0.000231	CcSEcCtD
Everolimus—Skin disorder—Ramipril—type 2 diabetes mellitus	5.58e-05	0.00023	CcSEcCtD
Everolimus—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	5.55e-05	0.000229	CcSEcCtD
Everolimus—Feeling abnormal—Losartan—type 2 diabetes mellitus	5.52e-05	0.000228	CcSEcCtD
Everolimus—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	5.48e-05	0.000226	CcSEcCtD
Everolimus—Dizziness—Valsartan—type 2 diabetes mellitus	5.48e-05	0.000226	CcSEcCtD
Everolimus—Anorexia—Ramipril—type 2 diabetes mellitus	5.47e-05	0.000226	CcSEcCtD
Everolimus—Dizziness—Orlistat—type 2 diabetes mellitus	5.41e-05	0.000223	CcSEcCtD
Everolimus—Asthenia—Metformin—type 2 diabetes mellitus	5.41e-05	0.000223	CcSEcCtD
Everolimus—Hypotension—Ramipril—type 2 diabetes mellitus	5.37e-05	0.000221	CcSEcCtD
Everolimus—Nausea—Gliclazide—type 2 diabetes mellitus	5.35e-05	0.000221	CcSEcCtD
Everolimus—Pruritus—Metformin—type 2 diabetes mellitus	5.33e-05	0.00022	CcSEcCtD
Everolimus—Abdominal pain—Losartan—type 2 diabetes mellitus	5.29e-05	0.000218	CcSEcCtD
Everolimus—Body temperature increased—Losartan—type 2 diabetes mellitus	5.29e-05	0.000218	CcSEcCtD
Everolimus—Vomiting—Valsartan—type 2 diabetes mellitus	5.26e-05	0.000217	CcSEcCtD
Everolimus—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	5.24e-05	0.000216	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	5.23e-05	0.000216	CcSEcCtD
Everolimus—Rash—Valsartan—type 2 diabetes mellitus	5.22e-05	0.000215	CcSEcCtD
Everolimus—Dermatitis—Valsartan—type 2 diabetes mellitus	5.22e-05	0.000215	CcSEcCtD
Everolimus—Vomiting—Orlistat—type 2 diabetes mellitus	5.2e-05	0.000215	CcSEcCtD
Everolimus—Insomnia—Ramipril—type 2 diabetes mellitus	5.19e-05	0.000214	CcSEcCtD
Everolimus—Headache—Valsartan—type 2 diabetes mellitus	5.19e-05	0.000214	CcSEcCtD
Everolimus—Diarrhoea—Metformin—type 2 diabetes mellitus	5.16e-05	0.000213	CcSEcCtD
Everolimus—Rash—Orlistat—type 2 diabetes mellitus	5.16e-05	0.000213	CcSEcCtD
Everolimus—Paraesthesia—Ramipril—type 2 diabetes mellitus	5.16e-05	0.000213	CcSEcCtD
Everolimus—Dermatitis—Orlistat—type 2 diabetes mellitus	5.15e-05	0.000213	CcSEcCtD
Everolimus—Headache—Orlistat—type 2 diabetes mellitus	5.13e-05	0.000211	CcSEcCtD
Everolimus—Dyspnoea—Ramipril—type 2 diabetes mellitus	5.12e-05	0.000211	CcSEcCtD
Everolimus—Asthenia—Irbesartan—type 2 diabetes mellitus	5.11e-05	0.000211	CcSEcCtD
Everolimus—Somnolence—Ramipril—type 2 diabetes mellitus	5.1e-05	0.000211	CcSEcCtD
Everolimus—Dyspepsia—Ramipril—type 2 diabetes mellitus	5.05e-05	0.000209	CcSEcCtD
Everolimus—Pruritus—Irbesartan—type 2 diabetes mellitus	5.03e-05	0.000208	CcSEcCtD
Everolimus—Decreased appetite—Ramipril—type 2 diabetes mellitus	4.99e-05	0.000206	CcSEcCtD
Everolimus—Dizziness—Metformin—type 2 diabetes mellitus	4.99e-05	0.000206	CcSEcCtD
Everolimus—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	4.96e-05	0.000205	CcSEcCtD
Everolimus—Fatigue—Ramipril—type 2 diabetes mellitus	4.95e-05	0.000204	CcSEcCtD
Everolimus—Hypersensitivity—Losartan—type 2 diabetes mellitus	4.93e-05	0.000204	CcSEcCtD
Everolimus—Nausea—Valsartan—type 2 diabetes mellitus	4.92e-05	0.000203	CcSEcCtD
Everolimus—Constipation—Ramipril—type 2 diabetes mellitus	4.91e-05	0.000203	CcSEcCtD
Everolimus—Diarrhoea—Irbesartan—type 2 diabetes mellitus	4.87e-05	0.000201	CcSEcCtD
Everolimus—Nausea—Orlistat—type 2 diabetes mellitus	4.86e-05	0.000201	CcSEcCtD
Everolimus—Asthenia—Losartan—type 2 diabetes mellitus	4.8e-05	0.000198	CcSEcCtD
Everolimus—Vomiting—Metformin—type 2 diabetes mellitus	4.79e-05	0.000198	CcSEcCtD
Everolimus—Rash—Metformin—type 2 diabetes mellitus	4.75e-05	0.000196	CcSEcCtD
Everolimus—Dermatitis—Metformin—type 2 diabetes mellitus	4.75e-05	0.000196	CcSEcCtD
Everolimus—Pruritus—Losartan—type 2 diabetes mellitus	4.74e-05	0.000195	CcSEcCtD
Everolimus—Feeling abnormal—Ramipril—type 2 diabetes mellitus	4.73e-05	0.000195	CcSEcCtD
Everolimus—Headache—Metformin—type 2 diabetes mellitus	4.72e-05	0.000195	CcSEcCtD
Everolimus—Dizziness—Irbesartan—type 2 diabetes mellitus	4.71e-05	0.000194	CcSEcCtD
Everolimus—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	4.7e-05	0.000194	CcSEcCtD
Everolimus—Diarrhoea—Losartan—type 2 diabetes mellitus	4.58e-05	0.000189	CcSEcCtD
Everolimus—Abdominal pain—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000187	CcSEcCtD
Everolimus—Body temperature increased—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000187	CcSEcCtD
Everolimus—Vomiting—Irbesartan—type 2 diabetes mellitus	4.52e-05	0.000187	CcSEcCtD
Everolimus—Rash—Irbesartan—type 2 diabetes mellitus	4.49e-05	0.000185	CcSEcCtD
Everolimus—Dermatitis—Irbesartan—type 2 diabetes mellitus	4.48e-05	0.000185	CcSEcCtD
Everolimus—Nausea—Metformin—type 2 diabetes mellitus	4.48e-05	0.000185	CcSEcCtD
Everolimus—Headache—Irbesartan—type 2 diabetes mellitus	4.46e-05	0.000184	CcSEcCtD
Everolimus—Dizziness—Losartan—type 2 diabetes mellitus	4.43e-05	0.000183	CcSEcCtD
Everolimus—Vomiting—Losartan—type 2 diabetes mellitus	4.26e-05	0.000176	CcSEcCtD
Everolimus—Hypersensitivity—Ramipril—type 2 diabetes mellitus	4.23e-05	0.000175	CcSEcCtD
Everolimus—Nausea—Irbesartan—type 2 diabetes mellitus	4.23e-05	0.000174	CcSEcCtD
Everolimus—Rash—Losartan—type 2 diabetes mellitus	4.22e-05	0.000174	CcSEcCtD
Everolimus—Dermatitis—Losartan—type 2 diabetes mellitus	4.22e-05	0.000174	CcSEcCtD
Everolimus—Headache—Losartan—type 2 diabetes mellitus	4.2e-05	0.000173	CcSEcCtD
Everolimus—Asthenia—Ramipril—type 2 diabetes mellitus	4.12e-05	0.00017	CcSEcCtD
Everolimus—Pruritus—Ramipril—type 2 diabetes mellitus	4.06e-05	0.000168	CcSEcCtD
Everolimus—Nausea—Losartan—type 2 diabetes mellitus	3.98e-05	0.000164	CcSEcCtD
Everolimus—Diarrhoea—Ramipril—type 2 diabetes mellitus	3.93e-05	0.000162	CcSEcCtD
Everolimus—Dizziness—Ramipril—type 2 diabetes mellitus	3.8e-05	0.000157	CcSEcCtD
Everolimus—Vomiting—Ramipril—type 2 diabetes mellitus	3.65e-05	0.000151	CcSEcCtD
Everolimus—Rash—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000149	CcSEcCtD
Everolimus—Dermatitis—Ramipril—type 2 diabetes mellitus	3.62e-05	0.000149	CcSEcCtD
Everolimus—Headache—Ramipril—type 2 diabetes mellitus	3.6e-05	0.000148	CcSEcCtD
Everolimus—Nausea—Ramipril—type 2 diabetes mellitus	3.41e-05	0.000141	CcSEcCtD
Everolimus—FKBP1A—Disease—INS—type 2 diabetes mellitus	2.34e-05	0.000175	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCKAR—type 2 diabetes mellitus	2.33e-05	0.000174	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LPL—type 2 diabetes mellitus	2.29e-05	0.000171	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT2—type 2 diabetes mellitus	2.27e-05	0.00017	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT2—type 2 diabetes mellitus	2.26e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—type 2 diabetes mellitus	2.25e-05	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	2.24e-05	0.000167	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SERPINE1—type 2 diabetes mellitus	2.15e-05	0.000161	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	2.15e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3R1—type 2 diabetes mellitus	2.15e-05	0.00016	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	2.11e-05	0.000158	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	2.11e-05	0.000158	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IAPP—type 2 diabetes mellitus	2.1e-05	0.000157	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INSR—type 2 diabetes mellitus	2.08e-05	0.000156	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—BCL2—type 2 diabetes mellitus	2.07e-05	0.000154	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3R1—type 2 diabetes mellitus	2.06e-05	0.000154	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—C3—type 2 diabetes mellitus	2.06e-05	0.000154	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3R1—type 2 diabetes mellitus	2.05e-05	0.000153	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOS3—type 2 diabetes mellitus	2.05e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TRPC6—type 2 diabetes mellitus	2.05e-05	0.000153	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFBR2—type 2 diabetes mellitus	2.04e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR2—type 2 diabetes mellitus	2.03e-05	0.000152	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—RELA—type 2 diabetes mellitus	2.02e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—type 2 diabetes mellitus	2e-05	0.000149	CbGpPWpGaD
Everolimus—MTOR—Disease—CDKN2B—type 2 diabetes mellitus	1.97e-05	0.000148	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.97e-05	0.000147	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.96e-05	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AGT—type 2 diabetes mellitus	1.96e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—AGER—type 2 diabetes mellitus	1.96e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—ADCY5—type 2 diabetes mellitus	1.95e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.95e-05	0.000146	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—RELA—type 2 diabetes mellitus	1.94e-05	0.000145	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.93e-05	0.000144	CbGpPWpGaD
Everolimus—MTOR—Disease—APOB—type 2 diabetes mellitus	1.92e-05	0.000144	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—LEP—type 2 diabetes mellitus	1.92e-05	0.000143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—type 2 diabetes mellitus	1.92e-05	0.000143	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.9e-05	0.000142	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.89e-05	0.000141	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.89e-05	0.000141	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD36—type 2 diabetes mellitus	1.89e-05	0.000141	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—type 2 diabetes mellitus	1.88e-05	0.00014	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—type 2 diabetes mellitus	1.88e-05	0.00014	CbGpPWpGaD
Everolimus—MTOR—Immune System—PPP2CA—type 2 diabetes mellitus	1.87e-05	0.00014	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—BHMT—type 2 diabetes mellitus	1.85e-05	0.000139	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.84e-05	0.000138	CbGpPWpGaD
Everolimus—MTOR—Disease—LPL—type 2 diabetes mellitus	1.84e-05	0.000137	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.83e-05	0.000137	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.81e-05	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.8e-05	0.000135	CbGpPWpGaD
Everolimus—MTOR—Disease—ADCY5—type 2 diabetes mellitus	1.8e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.79e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.79e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Immune System—C3—type 2 diabetes mellitus	1.79e-05	0.000134	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.77e-05	0.000132	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—type 2 diabetes mellitus	1.73e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Disease—PPP2CA—type 2 diabetes mellitus	1.72e-05	0.000129	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—type 2 diabetes mellitus	1.72e-05	0.000128	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	1.71e-05	0.000128	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS2—type 2 diabetes mellitus	1.71e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—CRP—type 2 diabetes mellitus	1.71e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NFKB1—type 2 diabetes mellitus	1.7e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Disease—CCR5—type 2 diabetes mellitus	1.69e-05	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—CALM1—type 2 diabetes mellitus	1.67e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.67e-05	0.000125	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—type 2 diabetes mellitus	1.65e-05	0.000124	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GCG—type 2 diabetes mellitus	1.64e-05	0.000123	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.64e-05	0.000123	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—INS—type 2 diabetes mellitus	1.64e-05	0.000122	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	1.64e-05	0.000122	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGDS—type 2 diabetes mellitus	1.62e-05	0.000121	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AANAT—type 2 diabetes mellitus	1.62e-05	0.000121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.61e-05	0.000121	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	1.61e-05	0.00012	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.61e-05	0.00012	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—SRC—type 2 diabetes mellitus	1.59e-05	0.000119	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	1.59e-05	0.000118	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	1.58e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—type 2 diabetes mellitus	1.58e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS2—type 2 diabetes mellitus	1.57e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Immune System—PRKCB—type 2 diabetes mellitus	1.57e-05	0.000118	CbGpPWpGaD
Everolimus—MTOR—Immune System—ICAM1—type 2 diabetes mellitus	1.57e-05	0.000117	CbGpPWpGaD
Everolimus—MTOR—Disease—CALM1—type 2 diabetes mellitus	1.55e-05	0.000116	CbGpPWpGaD
Everolimus—MTOR—Disease—APOE—type 2 diabetes mellitus	1.54e-05	0.000115	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPD2—type 2 diabetes mellitus	1.54e-05	0.000115	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CDO1—type 2 diabetes mellitus	1.54e-05	0.000115	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—type 2 diabetes mellitus	1.52e-05	0.000114	CbGpPWpGaD
Everolimus—MTOR—Disease—APOA1—type 2 diabetes mellitus	1.52e-05	0.000114	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SRC—type 2 diabetes mellitus	1.52e-05	0.000113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	1.51e-05	0.000112	CbGpPWpGaD
Everolimus—MTOR—Immune System—IRS1—type 2 diabetes mellitus	1.49e-05	0.000111	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AK1—type 2 diabetes mellitus	1.47e-05	0.00011	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	1.44e-05	0.000107	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	1.44e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS2—type 2 diabetes mellitus	1.44e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.43e-05	0.000107	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.41e-05	0.000106	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—type 2 diabetes mellitus	1.4e-05	0.000105	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AVP—type 2 diabetes mellitus	1.39e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.39e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—type 2 diabetes mellitus	1.39e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.39e-05	0.000104	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.38e-05	0.000103	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT2—type 2 diabetes mellitus	1.38e-05	0.000103	CbGpPWpGaD
Everolimus—MTOR—Disease—IRS1—type 2 diabetes mellitus	1.37e-05	0.000103	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—type 2 diabetes mellitus	1.36e-05	0.000101	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A4—type 2 diabetes mellitus	1.35e-05	0.000101	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MAT1A—type 2 diabetes mellitus	1.35e-05	0.000101	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RELA—type 2 diabetes mellitus	1.35e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOB—type 2 diabetes mellitus	1.35e-05	0.000101	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.34e-05	0.0001	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—type 2 diabetes mellitus	1.34e-05	9.99e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—type 2 diabetes mellitus	1.33e-05	9.94e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.33e-05	9.91e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—INS—type 2 diabetes mellitus	1.32e-05	9.84e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.31e-05	9.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.31e-05	9.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.31e-05	9.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.31e-05	9.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.31e-05	9.77e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LPL—type 2 diabetes mellitus	1.29e-05	9.62e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT2—type 2 diabetes mellitus	1.27e-05	9.51e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.27e-05	9.46e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.26e-05	9.42e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3R1—type 2 diabetes mellitus	1.25e-05	9.34e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	1.22e-05	9.12e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SERPINE1—type 2 diabetes mellitus	1.21e-05	9.03e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	1.21e-05	9.02e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2—type 2 diabetes mellitus	1.2e-05	8.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.2e-05	8.93e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.2e-05	8.93e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCR5—type 2 diabetes mellitus	1.19e-05	8.86e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—RELA—type 2 diabetes mellitus	1.18e-05	8.79e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.16e-05	8.71e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—C3—type 2 diabetes mellitus	1.16e-05	8.66e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—NOS3—type 2 diabetes mellitus	1.15e-05	8.63e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3R1—type 2 diabetes mellitus	1.15e-05	8.63e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	1.15e-05	8.62e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	1.14e-05	8.53e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.11e-05	8.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.11e-05	8.3e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.11e-05	8.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	1.11e-05	8.26e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS2—type 2 diabetes mellitus	1.1e-05	8.24e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGT—type 2 diabetes mellitus	1.1e-05	8.23e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CALM1—type 2 diabetes mellitus	1.08e-05	8.09e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—LEP—type 2 diabetes mellitus	1.08e-05	8.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—type 2 diabetes mellitus	1.08e-05	8.06e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—type 2 diabetes mellitus	1.07e-05	7.99e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOA1—type 2 diabetes mellitus	1.07e-05	7.97e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	1.07e-05	7.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	1.07e-05	7.96e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—type 2 diabetes mellitus	1.06e-05	7.94e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—type 2 diabetes mellitus	1.06e-05	7.89e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	1.04e-05	7.74e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	1.03e-05	7.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	1.03e-05	7.66e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—type 2 diabetes mellitus	1.02e-05	7.64e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	1.02e-05	7.6e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	1.01e-05	7.53e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—NFKB1—type 2 diabetes mellitus	9.92e-06	7.42e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	9.9e-06	7.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	9.9e-06	7.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	9.9e-06	7.4e-05	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—type 2 diabetes mellitus	9.87e-06	7.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IRS1—type 2 diabetes mellitus	9.62e-06	7.19e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	9.5e-06	7.1e-05	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	9.47e-06	7.08e-05	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—type 2 diabetes mellitus	9.43e-06	7.05e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	9.32e-06	6.96e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	9.31e-06	6.96e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—type 2 diabetes mellitus	9.25e-06	6.91e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—INS—type 2 diabetes mellitus	9.22e-06	6.89e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCL2—type 2 diabetes mellitus	9.07e-06	6.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1—type 2 diabetes mellitus	8.92e-06	6.66e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT2—type 2 diabetes mellitus	8.91e-06	6.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	8.72e-06	6.52e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—type 2 diabetes mellitus	8.54e-06	6.38e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	8.47e-06	6.33e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	8.42e-06	6.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	8.42e-06	6.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	8.42e-06	6.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	8.42e-06	6.29e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—type 2 diabetes mellitus	8.11e-06	6.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOS3—type 2 diabetes mellitus	8.08e-06	6.04e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	8.08e-06	6.04e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	8.07e-06	6.03e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—type 2 diabetes mellitus	7.63e-06	5.7e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RELA—type 2 diabetes mellitus	7.61e-06	5.69e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	7.51e-06	5.61e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—type 2 diabetes mellitus	7.48e-06	5.59e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—type 2 diabetes mellitus	7.16e-06	5.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	7.01e-06	5.24e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	6.87e-06	5.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	6.87e-06	5.13e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.86e-06	5.13e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	6.73e-06	5.03e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.69e-06	5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.69e-06	5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.69e-06	5e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.65e-06	4.97e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.61e-06	4.94e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6.53e-06	4.88e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—type 2 diabetes mellitus	6.48e-06	4.85e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	6.45e-06	4.82e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	6.42e-06	4.79e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—type 2 diabetes mellitus	6.23e-06	4.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	6e-06	4.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	6e-06	4.48e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	6e-06	4.48e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—type 2 diabetes mellitus	5.98e-06	4.47e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.89e-06	4.4e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.84e-06	4.36e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.82e-06	4.35e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—type 2 diabetes mellitus	5.75e-06	4.3e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—type 2 diabetes mellitus	5.75e-06	4.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.71e-06	4.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.49e-06	4.1e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.43e-06	4.06e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.43e-06	4.06e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.34e-06	3.99e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—type 2 diabetes mellitus	5.31e-06	3.96e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.24e-06	3.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	5.2e-06	3.89e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	5.2e-06	3.89e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.48e-06	3.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.48e-06	3.35e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.46e-06	3.34e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.4e-06	3.29e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	4.28e-06	3.2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	4.16e-06	3.11e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	4.08e-06	3.05e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—type 2 diabetes mellitus	4.03e-06	3.01e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	4e-06	2.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.98e-06	2.98e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.88e-06	2.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.83e-06	2.86e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.72e-06	2.78e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.68e-06	2.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.61e-06	2.7e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.49e-06	2.61e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.43e-06	2.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.42e-06	2.56e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.38e-06	2.53e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.98e-06	2.23e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.92e-06	2.18e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.68e-06	2e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.56e-06	1.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.56e-06	1.92e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.34e-06	1.75e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.18e-06	8.81e-06	CbGpPWpGaD
